keyword
MENU ▼
Read by QxMD icon Read
search

Rotigotine

keyword
https://www.readbyqxmd.com/read/29668694/the-efficacy-and-tolerability-of-rotigotine-on-patients-with-periodic-limb-movement-in-sleep-a-systematic-review-and-meta-analysis
#1
Meng-Ni Wu, Ping-Tao Tseng, Tien-Yu Chen, Yen-Wen Chen, Li-Min Liou, Pao-Yen Lin, Chung-Yao Hsu
OBJECTIVE: There is still no consensus on the treatment for periodic limb movement in sleep (PLMS). This study aimed to determine the efficacy and tolerability of rotigotine in patients suffering from PLMS. METHODS: Publications listed in PubMed, ScienceDirect, The Cochrane Library, and ClinicalTrials.gov were reviewed to assess the efficacy of rotigotine on PLMS. Analyses of PLMS frequency before and after rotigotine treatments (pre- and post-intervention studies) and PLMS frequency between placebo and rotigotine treatments (placebo-controlled trial studies) were included in our study...
2018: PloS One
https://www.readbyqxmd.com/read/29602660/management-of-treatment-failure-in-restless-legs-syndrome-willis-ekbom-disease
#2
REVIEW
Diego Garcia-Borreguero, Irene Cano-Pumarega, Rafael Marulanda
Dopaminergic drugs have been widely used over the last decades for the treatment of restless legs syndrome (RLS)/Willis-Ekbom disease (WED). While the majority of studies show an initial improvement in symptoms, longer studies and clinical experience show that either treatment efficacy decreases with time, and/or augmentation develops: dopaminergic augmentation has been reported to be the main reason for treatment discontinuation and treatment failure in RLS/WED. The current review discusses the main reasons for treatment failure in RLS/WED and outlines the most recent expert-based strategies to prevent and manage it...
January 9, 2018: Sleep Medicine Reviews
https://www.readbyqxmd.com/read/29563862/caffeine-protects-dopaminergic-neurons-from-dopamine-induced-neurodegeneration-via-synergistic-adenosine-dopamine-d2-like-receptor-interactions-in-transgenic-caenorhabditis-elegans
#3
Rafael V M Manalo, Paul M B Medina
Previous studies have suggested that caffeine reduces the risk of L-DOPA-induced dyskinesia. However, caffeine is also known to promote dopamine signaling, which seemingly contradicts this observed effect. To this end, the study aimed to clarify the mechanism of caffeine neuroprotection in vivo when excess dopamine is present. Transgenic Caenorhabditis elegans (UA57) overproducing dopamine was exposed to caffeine for 7 days and monitored by observing GFP-tagged dopaminergic (DA) neurons via fluorescence microscopy...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29520899/pain-in-parkinson-disease-facts-and-uncertainties
#4
Angelo Antonini, Michele Tinazzi, Giovanni Abbruzzese, Alfredo Berardelli, K Ray Chaudhuri, Giovanni Defazio, Joaquim Ferreira, Pablo Martinez-Martin, Claudia Trenkwalder, Olivier Rascol
BACKGROUND: Pain is one of the most common and troublesome non-motor symptoms of Parkinson's disease; it can appear at any time during the disease, and it is often present before diagnosis. However, there is little or no consensus on its definition. METHODS: An expert group of clinicians with relevant research experience met to review the existing evidence, and to identify gaps in our understanding towards an optimized therapy of pain in Parkinson's disease. RESULTS: Key findings from epidemiologic, neurophysiologic, neuroimaging and clinical studies are reviewed...
March 9, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29484495/an-observational-study-of-rotigotine-transdermal-patch-and-other-currently-prescribed-therapies-in-patients-with-parkinson-s-disease
#5
Thomas Müller, Eduardo Tolosa, Letitia Badea, Mahnaz Asgharnejad, Frank Grieger, Michael Markowitz, Xavier Nondonfaz, Lars Bauer, Lars Timmermann
Real-world data from large cohorts of patients with Parkinson's disease on the long-term effectiveness of different dopamine-substituting drug therapies are rare. The objective of this study was to obtain information on real-world management of PD with dopamine-substituting drugs. SP0854 (NCT00599339) was a prospective, multicenter, non-interventional, multiple-cohort, post-authorization safety study of rotigotine versus other dopaminergic therapies. The study was also part of a European Medicines Agency risk-management plan for the non-ergoline dopamine agonist rotigotine, focussing on cardiovalvular fibrosis...
February 26, 2018: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29461870/randomized-double-blind-crossover-study-of-the-adhesiveness-of-two-formulations-of-rotigotine-transdermal-patch-in-patients-with-parkinson-s-disease
#6
Jan-Peer Elshoff, Lars Bauer, Nadine Goldammer, Marga Oortgiesen, Hanna Pesch, Lars Timmermann
OBJECTIVE: In patch-based transdermal drug delivery, adhesiveness is critical for safe and effective treatment, especially in Parkinson's disease (PD) where excessive sweating is common. This study compared the adhesiveness of two transdermal patch formulations of rotigotine (improved room temperature-stable [PR2.3.1/Treatment A] and intermediate cold storage product [PR2.1.1/Treatment B]), using the largest patch size (40 cm2 ). METHODS: PD0018 (NCT02230904) was a multicenter, randomized, double-blind, crossover study...
February 20, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29442177/effectiveness-of-rotigotine-plus-intensive-and-goal-based-rehabilitation-versus-rotigotine-alone-in-de-novo-parkinsonian-subjects-a-randomized-controlled-trial-with-18-month-follow-up
#7
D Ferrazzoli, P Ortelli, G Riboldazzi, R Maestri, G Frazzitta
BACKGROUND: Dopamine Replacement Therapy (DRT) represents the most effective treatment for Parkinson's disease (PD). Nevertheless, several symptoms are unresponsive to treatment and its long-term use leads to serious side effects. To optimize the pharmacological management of PD, dopamine-agonists are often prescribed to "de-novo" patients. Moreover, several studies have shown the effectiveness and the synergic effect of rehabilitation in treating PD. OBJECTIVE: To evaluate the synergism between DRT and rehabilitation in treating PD, by investigating the short and the long-term effectiveness of a multidisciplinary, intensive and goal-based rehabilitation treatment (MIRT) in a group of patients treated with Rotigotine...
February 13, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29391788/lactoferrin-modified-rotigotine-nanoparticles-for-enhanced-nose-to-brain-delivery-lesa-ms-ms-based-drug-biodistribution-pharmacodynamics-and-neuroprotective-effects
#8
Xiuju Yan, Lixiao Xu, Chenchen Bi, Dongyu Duan, Liuxiang Chu, Xin Yu, Zimei Wu, Aiping Wang, Kaoxiang Sun
Introduction: Efficient delivery of rotigotine into the brain is crucial for obtaining maximum therapeutic efficacy for Parkinson's disease (PD). Therefore, in the present study, we prepared lactoferrin-modified rotigotine nanoparticles (Lf-R-NPs) and studied their biodistribution, pharmacodynamics, and neuroprotective effects following nose-to-brain delivery in the rat 6-hydroxydopamine model of PD. Materials and methods: The biodistribution of rotigotine nanoparticles (R-NPs) and Lf-R-NPs after intranasal administration was assessed by liquid extraction surface analysis coupled with tandem mass spectrometry...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29339630/comparison-of-the-efficacy-of-different-drugs-on-non-motor-symptoms-of-parkinson-s-disease-a-network-meta-analysis
#9
Bao-Dong Li, Jing-Jun Cui, Jia Song, Ce Qi, Pei-Feng Ma, Ya-Rong Wang, Jing Bai
BACKGROUND/AIMS: A network meta-analysis is used to compare the efficacy of ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, for non-motor symptoms in Parkinson's disease (PD). METHODS: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD...
2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29332198/drug-delivery-and-transport-into-the-central-circulation-an-example-of-zero-order-in-vivo-absorption-of-rotigotine-from-a-transdermal-patch-formulation
#10
Willi Cawello, Marina Braun, Jens-Otto Andreas
BACKGROUND AND OBJECTIVE: Pharmacokinetic studies using deconvolution methods and non-compartmental analysis to model clinical absorption of drugs are not well represented in the literature. The purpose of this research was (1) to define the system of equations for description of rotigotine (a dopamine receptor agonist delivered via a transdermal patch) absorption based on a pharmacokinetic model and (2) to describe the kinetics of rotigotine disposition after single and multiple dosing...
January 13, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29249180/the-effects-of-transdermal-rotigotine-on-non-motor-symptoms-of-parkinson-s-disease-a-multicentre-observational-retrospective-post-marketing-study
#11
Francesc Valldeoriola, Antonio Salvador, José Maria Gómez-Arguelles, José Marey, Miguel Moya, Ángel Ayuga, Francisco Ramírez
AIM: This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease. MATERIALS AND METHODS: The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months...
April 2018: International Journal of Neuroscience
https://www.readbyqxmd.com/read/29221778/long-term-treatment-with-dopamine-d3-receptor-agonists-induces-a-behavioral-switch-that-can-be-rescued-by-blocking-the-dopamine-d1-receptor
#12
Mai-Lynne Dinkins, Perrine Lallemand, Stefan Clemens
Restless legs syndrome (RLS) is commonly treated with the dopamine agonists pramipexole, and rotigotine, which target the inhibitory dopamine receptor subtype D3R. While initially highly effective, these compounds lose their efficacy in treating RLS over time, and long-term therapy regularly leads to a worsening of the symptoms (augmentation). This dopamine agonist-induced augmentation has become a prime concern in the treatment of RLS, and while alternate therapies are being proposed, the mechanisms leading to augmentation remain opaque...
December 2017: Sleep Medicine
https://www.readbyqxmd.com/read/29198453/effects-of-rotigotine-on-clinical-symptoms-quality-of-life-and-sleep-hygiene-adequacy-in-haemodialysis-associated-restless-legs-syndrome
#13
Vicent Esteve, Jose Carneiro, Gabriel Salazar, Mónica Pou, Irati Tapia, Miquel Fulquet, Verónica Duarte, Anna Saurina, Fátima Moreno, Manel Ramírez de Arellano
BACKGROUND: Restless legs syndrome (RLS) is a neurological disorder characterised by bothersome symptoms associated with impaired quality of life and sleep hygiene. Rotigotine is a novel therapeutic alternative, although few studies have been published in patients on haemodialysis (HD) with RLS treated with rotigotine. OBJECTIVES: 1.- To establish the prevalence of RLS in our HD unit. 2.- To evaluate the efficacy and safety profile of rotigotine and its effect on symptoms, quality of life and sleep hygiene in our HD population with RLS...
January 2018: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/29164312/efficacy-and-safety-of-rotigotine-in-elderly-patients-with-parkinson-s-disease-in-comparison-with-the-non-elderly-a-post-hoc-analysis-of-randomized-double-blind-placebo-controlled-trials
#14
Masahiro Nomoto, Hirotaka Iwaki, Hiroyuki Kondo, Masaya Sakurai
Rotigotine-a non-ergot dopamine agonist-has two advantages; it can stimulate all dopamine receptors (D1-D5) like innate dopamine, and its transdermal administration provides continuous dopaminergic stimulation. The age of the patient impacts the effect and adverse events of anti-parkinsonian treatment. We conducted a post hoc analysis on three randomized, double-blind, placebo-controlled trials performed in Japan to clarify the difference of anti-parkinsonian treatment in elderly and non-elderly patients. Data from two combination therapy trials (with levodopa) in advanced stage Parkinson's disease patients and one monotherapy trial in early stage patients were pooled and grouped by age (non-elderly aged < 70, elderly aged 70 +)...
February 2018: Journal of Neurology
https://www.readbyqxmd.com/read/28993209/rotigotine-a-dopamine-receptor-agonist-increased-bdnf-protein-levels-in-the-rat-cortex-and-hippocampus
#15
Naoki Adachi, Aya Yoshimura, Shuichi Chiba, Shintaro Ogawa, Hiroshi Kunugi
Brain-derived neurotrophic factor (BDNF) critically controls the fate and function of the neuronal network and has received much attention as a target of many brain diseases. Dopaminergic system dysfunction has also been implicated in a variety of neuropsychiatric diseases. Rotigotine, a non-ergot dopamine receptor agonist, is used in the treatment of Parkinson's disease and restless legs syndrome. To investigate the effects of rotigotine on neuronal functions both in vivo and in vitro, rats and primary cortical neurons were administered rotigotine, and the mRNA and protein expression levels of BDNF, its receptor TrkB and downstream signaling molecules, and synaptic proteins were determined...
January 1, 2018: Neuroscience Letters
https://www.readbyqxmd.com/read/28900068/-efficacy-of-topical-agents-for-symptomatic-treatment-of-rotigotine-patch-induced-skin-disorders
#16
Yuki Yasutaka, Shinsuke Fujioka, Hirotomo Shibaguchi, Fumiaki Kiyomi, Koyomi Hara, Kentaro Ogata, Yoshio Tsuboi, Hidetoshi Kamimura
Since the effect of a percutaneous absorption-type dopamine agonist (DA) preparation, rotigotine patch, stably persists by once-a-day application, this dosage form is appropriate for Parkinson's disease patients showing levodopa induced wearing off phenomenon. On the other hand, skin disorders, mainly application site reaction, are characteristic problems associated with use of the patch. In this study, to clarify the influence of a topical agent used to prevent or treat rotigotine patch-induced skin disorder on continuation of the patch application, patients who started rotigotine patch application at our hospital were retrospectively surveyed...
September 2017: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/28890931/rotigotine-transdermal-patch-and-sleep-in-parkinson-s-disease-where-are-we-now
#17
REVIEW
Miguel Rosa-Grilo, Mubasher A Qamar, Raquel N Taddei, Javier Pagonabarraga, Jaime Kulisevsky, Anna Sauerbier, K Ray Chaudhuri
A wide range of sleep dysfunction complicates Parkinson's disease during its course from prodromal to palliative stage. It is now increasingly acknowledged that sleep disturbances are thus integral to the disease and pose a significant burden impacting on quality of life of patients. Sleep fragmentation, restless legs syndrome, nocturia, and nocturnal pain are regarded as one of the main components of night-time sleep dysfunction with possible secondary impact on cognition and well-being. The role of dopaminergic therapies, particularly using a continuous drug delivery strategy in managing some of these sleep issues, have been reported but the overall concept remains unclear...
2017: NPJ Parkinson's Disease
https://www.readbyqxmd.com/read/28888061/gabapentin-enacarbil-pregabalin-and-rotigotine-are-equally-effective-in-restless-legs-syndrome-a-comparative-meta-analysis
#18
REVIEW
I H Iftikhar, L Alghothani, L M Trotti
To synthesize evidence from available randomized controlled trials (RCT) to compare the efficacies of dopaminergic drugs (pramipexole, ropinirole and rotigotine) and α-2-δ ligands (gabapentin enacarbil and pregabalin) for the treatment of restless legs syndrome (RLS). We searched PubMed for all eligible RCTs. Network meta-analysis using frequentist methodology with random effect models was performed for mean changes in scores on the International RLS Study Group Rating Scale (IRLS) and for responder rates on Clinical Global Impressions-Improvement (CGI-I); analyzed as odds ratio (OR)...
September 9, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28872217/adverse-effects-produced-by-different-drugs-used-in-the-treatment-of-parkinson-s-disease-a-mixed-treatment-comparison
#19
Bao-Dong Li, Zhen-Yun Bi, Jing-Feng Liu, Wei-Jun Si, Qian-Qian Shi, Li-Peng Xue, Jing Bai
OBJECTIVE: This mixed treatment comparison is used to compare the adverse effects of eleven different drugs used to treat Parkinson's disease (PD). The drugs that we compare include the following: ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil, pergolide, and levodopa. METHODS: PubMed, EMBASE, and Cochrane Library were searched from the inception to December 2015. Our analysis combines the evidences of direct comparison and indirect comparison between various literatures...
October 2017: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/28845835/continuous-dopaminergic-stimulation-in-a-patient-treated-with-daytime-levodopa-carbidopa-intestinal-gel-and-overnight-rotigotine-a-case-report
#20
Paola Imbriani, Tommaso Schirinzi, Alessio D'Elia, Antonio Pisani
Patients with Parkinson's disease (PD) receiving long-term L-Dopa therapy eventually develop motor complications with unpredictable "on-off" response fluctuations and involuntary movements, leading to progressive disability. Hence, the search for alternative therapeutic choices based on continuous dopaminergic stimulation (CDS) becomes crucial for the treatment of advanced PD. Here, we describe the case of a 70-year-old man with a 9-year history of PD, treated with daytime levodopa-carbidopa intestinal gel (LCIG) and overnight Rotigotine transdermal patch...
August 23, 2017: Acta Bio-medica: Atenei Parmensis
keyword
keyword
56686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"